Savara SVRA
NASDAQ SVRA
$5.37 +0.00 (+0.00%)
As of: Sep 4, 2026 · 3:59 PM EDT

Savara (SVRA) Cash from Investing Activities (2010 - 2026)

Savara (SVRA) posted quarterly Cash from Investing Activities of $38.8 million for Q1 2026, up 32.22% year-over-year from $29.3 million in Q1 2025, and up 141.45% quarter-over-quarter from -$93.6 million in Q4 2025.

Analysis

Savara (SVRA) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Savara (SVRA) has reported Cash from Investing Activities for 17 consecutive years, with $38.8 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Cash from Investing Activities rose 32.22% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at -$9.0 million (up 58.0% YoY), while the FY2025 annual figure was -$18.4 million, up 53.83% from the prior year.
  • Cash from Investing Activities improved to $38.8 million in Q1 2026 per SVRA's latest filing, from -$93.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $53.7 million in Q1 2022 and bottomed at -$98.2 million in Q3 2024.
  • Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of $17.9 million in 2024.
  • Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 4569.64% — and 2024, when it surged 3036.18%.
  • Savara's Cash from Investing Activities stood at -$59.2 million in 2022, then jumped by 111.1% to $6.6 million in 2023, then jumped by 172.33% to $17.9 million in 2024, then slumped by 622.85% to -$93.6 million in 2025, then jumped by 141.45% to $38.8 million in 2026.
  • Business Quant data shows SVRA's Cash from Investing Activities at $38.8 million in Q1 2026, -$93.6 million in Q4 2025, and $21.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Savara 1.36 Bn 1.36 Bn - 32.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 32.60 Mn
Mar 31, 2026 38.78 Mn
Dec 31, 2025 -93.56 Mn
Sep 30, 2025 21.47 Mn
Jun 30, 2025 24.33 Mn
Mar 31, 2025 29.33 Mn
Dec 31, 2024 17.90 Mn
Sep 30, 2024 -98.17 Mn
Jun 30, 2024 29.54 Mn
Mar 31, 2024 10.79 Mn
Dec 31, 2023 6.57 Mn
Sep 30, 2023 -56.59 Mn
Jun 30, 2023 -1.01 Mn
Mar 31, 2023 -6.10 Mn
Dec 31, 2022 -59.21 Mn
Sep 30, 2022 33.00 Mn
Jun 30, 2022 25.20 Mn
Mar 31, 2022 53.67 Mn
Dec 31, 2021 -1.27 Mn
Sep 30, 2021 12.98 Mn